Transenterix Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:5em;'>T</div>
TRXC -- USA Stock  

USD 3.72  0.18  4.62%

With so much uncertainty about the healthcare space, it is fair to go over TransEnterix against current market trends. We are going to address the reasons why we are still confident in anticipation of a recovery. The returns on the market and returns on TransEnterix appear slightly correlated for the last few months. The appearance of strong basic indicators of the company suggests a short-term price swing for investors of TransEnterix. The upcoming quarterly report is expected on the 15th of March 2021. The stock is undergoing an active upward rally.
Published over a month ago
View all stories for Transenterix | View All Stories
Is TransEnterix (AMEX:TRXC) outlook still optimistic?
This firm's average rating is Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on TransEnterix market sentiment investors' perception of the future value of TransEnterix. Let us look at a few aspects of TransEnterix technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Transenterix. In general, we focus on analyzing Transenterix stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Transenterix's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Transenterix's intrinsic value. In addition to deriving basic predictive indicators for Transenterix, we also check how macroeconomic factors affect Transenterix price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Transenterix's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Transenterix in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Transenterix. Your research has to be compared to or analyzed against Transenterix's peers to derive any actionable benefits. When done correctly, Transenterix's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Transenterix.

How does Transenterix Stands against Peers?

Analyzing Transenterix competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Transenterix across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Transenterix Competition Details

How Transenterix utilizes its cash?

To perform a cash flow analysis of Transenterix, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Transenterix is receiving and how much cash it distributes out in a given period. The Transenterix cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Transenterix Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (84.51 Million)

Acquisition by Shameze Rampertab of 59200 shares of Transenterix subject to Rule 16b-3

Legal trades by Transenterix insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Transenterix insider trading alert for grant of restricted stock units by Shameze Rampertab, EVP Chief Financial Officer, on 8th of February 2021. This event was filed by Transenterix Inc with SEC on 2021-02-08. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at TransEnterix Variance

TransEnterix has current Variance of 253.16. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance 
 = 
SUM(RET DEV)2 
 = 
253.16
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare TransEnterix Variance to its closest peers:
TRXC
ABT
SYK
BIO
ZBH
TRXC253.16
ABT1.75
SYK3.4
BIO6.57
ZBH4.74

Another 3 percent rise for TransEnterix

Current skewness is at 3.4. As of the 23rd of January, TransEnterix has the Semi Deviation of 4.09, risk adjusted performance of 0.2655, and Coefficient Of Variation of 377.69. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of TransEnterix, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for TransEnterix, which can be compared to its competition. Please validate TransEnterix variance, as well as the relationship between the value at risk and skewness to decide if TransEnterix is priced more or less accurately, providing market reflects its prevalent price of 3.71 per share. Given that TransEnterix has jensen alpha of 4.15, we advise you to double-check TransEnterix's current market performance to make sure the company can sustain itself at a future point.

Our Final Perspective on TransEnterix

Whereas other companies under the medical devices industry are still a bit expensive, TransEnterix may offer a potential longer-term growth to investors. To conclude, as of the 23rd of January 2021, we believe that at this point, TransEnterix is abnormally volatile with very low odds of financial turmoil within the next 2 years. From a slightly different point of view, the entity appears to be overvalued. Our primary 30 days Buy-Hold-Sell recommendation on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Transenterix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com